THERAPEUTIC POTENTIAL OF METFORMIN: INFLUENCE ON CARBOHYDRATE, LIPID, CYTOCINE METABOLISM IN PATIENTS WITH COMORBID PATHOLOGY
DOI:
https://doi.org/10.21856/j-PEP.2012.3.05Keywords:
essential hypertension, type 2 diabetes mellitus, comcomorbid pathology, metformin, cytokinesAbstract
It investigates of metformin’s therapeutic potential and its influence on carbohydrate, lipid,
cytokine metabolism in patients with essential hypertension with accompained type 2 diabetes
mellitus. It shows that treatment with metformin significantly improves lipid metabolism in patients
with combined pathology. Metabolic effects of metformin lead to decreasing of body mass index,
proinflammatory cytokine — interleukine-6 plasma levels in patients with essential hypertension with
accompained type 2 diabetes mellitus. Positive pharmacologic effects of metformin are connected with
glycemic control, diminishing of insulin, glycated hemoglobine and insulineresistance index
References
Colwell, J. A. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome [Text] / J. A. Colwell // JAMA. — 2011. — Vol. 306 (2). — P. 215.
Rega, G. Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue [Text] / G. Rega, C. Kaun, T.W. Weiss // Circulation. — 2005. — Vol. 111. — P. 1938–1945.
New ADA/EASD Concensus recommends metformin at diagnosis of type 2 diabetes [Text] // Diabetes Care. — 2006. — Vol. 29 (8). — P. 1963–1972.
Scarpello, J. H. Improving survival with metformin: the evidence base today [Text] / J. H. Scarpello // Diabetes Metabol. — 2003. — Vol. 29 (6). — P. 36–43.
Increased subclinical atherosclerosis in young adults with metabolic syndrome: The Bogalusa Heart Study [Text] / W. S. Tzou, P. S. Douglas, S. R. Srinivasan [et al.] // J. Am. Coll. Cardiol. — 2005. — Vol. 46 (3). — P. 457–463.
Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definition of the metabolic syndrome in a prospective cohort stady [Text] / D. F. Laaksonen, H. M. Laaka, L. K. Niskanen [et al.] // Am. J. Epidemiol. — 2002. — Vol. 156. — P. 1070–1077.
Kirpichnikov D. Metformin. An Update [Text] / D. Kirpichnikov, S. I. McFarlane, J. R. Sowers //Ann. Intern. Med. — 2002. — Vol. 137. —
P. 25–33.
Daskalopoulou, S. S. Prevention and treatment of the metabolic syndrome [Text] / S. S. Daskalopoulou, D. P. Mikhailidis, M. Elisaf
//Angiology. — 2004. — Vol. 55 (6). — P. 3145–3152.
Metformin inhibits adenosine 5’–monophosphateactivated kinase activation and prevents increases in neuropeptide y expression in cultured hypothalamic neurons [Text] / C. Chau–Van, M. Gamba, R. Salvi [et al.] // Endocrinology. — 2007. — Vol. 148 (2). —P. 507–511.
Effect of metformin on glucagon–like peptide 1 (GLP–1) and leptin levels in obese nondiabetic subjects [Text] / E. Mannucci, A. Ognibene, F. Cremasco [et al.] // Diabetes Care. — 2001. — Vol. 24 (3). — P. 489–494.
Mamputu, J. C. Antiatherogenic properties of metformin: the experimental evidence [Text] / J. C. Mamputu, N. F. Wiernsperger, G. A. Renier // Diabetes Metabol. — 2003. — Vol. 29 (6). — P. 71–76.
UK Prospective Diabetes Stydy (UKPDS) Croup/ Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. — 1998. — Vol. 352. — P. 854–865.
Activation of the AMP–activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase [Text] / B. J. Davis, Z. Xie, B. Viollet, M. H. Zou // Diabetes. — 2006. — Vol. 55 (2). — P. 496–450.
De Aquiar, L. G. Metformin improves endothelial vascular reactivity in first–degree relatives of type diabetic patient with metabolic syndrome and normal glucose tolerance [Text] / L. G De Aquiar., L. R. Bahia, N. Villela // Diabetes Care. — 2006. — Vol. 29 (5). — P. 1083–1089.
Metformin reduces endothelial cell expression of oth the receptor for advanced glycation end products and lectin–like oxidized receptor 1 [Text] / N. Ouslimani, M. Mahrouf, J. Peynet [et al.] //Metabolism. — 2007. — Vol. 56 (3). — P. 308–313.
Grand, P. J. Beneficial effects of metformin on hemostasis and vascular function in max [Text] / P. J. Grand // Diabetes Metabol. — 2003. — Vol. 29 (6). — P. 45–52.
Hong, Y. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all–cause mortality — results of prospective analysis for the Atherosclerosis Risk in Communities study [Text] / Y. Hong, X. Jin, J. Mo // J. Intern. Med. —
— Vol. 262 (1). — P. 113–123.
Isoda, K. Metformin inhibits proinflammatory responses and nuclear factor–(nf-kb) in human vascular wall cells [Text] / K. Isoda, J. L. Young, A. Zirlik [et al.] // Arterioscler. Thromb. Vasc. Biol. — 2006. — Vol. 26 (3). — P. 611–617.
Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo [Text] / G. Rega, C. Kaun, S. Demyanets [et al.] // Arterioscler. Thromb. Vasc. Biol. — 2007. — Vol. 27 (7). — P. 1587–1595.
Relationship of total and abdominal adiposity with CRP and IL-6 in women / K. M. Rexrode, A. Pradhan, J. E. Manson [et al.] // Ann. Epidemiol. — 2003. — Vol. 13. — P. 674–682.
ISSN 
ISSN 
